Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2024.240 | A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma | Prof. HUI David Shu Cheong |
| 2015.703 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 in combination with Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects with Chronic Hepatitis B and who are currently not on Treatment |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2013.531 | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ADMINISTRATION OF A CHEMOKINE CCR2/5 RECEPTOR ANTAGONIST (PF-04634817) IN ADULTS WITH TYPE 2 DIABETES AND OVERT NEPHROPATHY | Dr Ozaki Risa |
| 2012.134 | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ADMINISTRATION OF A PHOSPHODIESTERASE 5 INHIBITOR (PF-00489791) IN ADULTS WITH TYPE 2 DIABETES AND OVERT NEPHROPATHY | Dr Ozaki Risa |
| 2009.163 | A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study of the Safety, Pharmacokinetics and Biological Effects of Intravenous Fosbretabulin in Asian Subjects with Polypoidal Choroidal Vasculopathy (PCV) | Dr Lai Timothy Yuk Yau |
| 2018.472 | A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined with Intravesical BCG in Participants with BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer (CheckMate 9UT: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9UT) |
Dr. POON Darren Ming Chun 潘明駿 |
| 2021.154 | A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073) |
Dr. CHAN Stephen Lam 陳林 |
| 2025.096 | A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer | Dr. LOONG Herbert Ho Fung |
| 2018.297 | A Phase 2, Randomized, Open-Label, Active-Controlled Study to Evaluate the Safety and Antiviral Activity of GS-9992 Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Chronic Hepatitis B (CHB) Subjects |
Prof. WONG Grace Lai Hung 陳力元教授 |
| 2018.344 | A Phase 2, Randomized, Open-Label, Active-Controlled Study to Evaluate the Safety and Antiviral Activity of GS-9992 Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Chronic Hepatitis B (CHB) Subjects |
Dr. AU Kenneth Hon Da 許祖紳醫生 |
| 2007.307 | A Phase 2, Randomized, Parallel Group, Multi-Center, Multi-National Study for the Evaluation of Safety and Efficacy of Two Fixed Dosages of DU-176b in Subjects with Non-Valvular Atrial Fibrillation | Prof. Yu Cheuk Man |
| 2021.147 | A Phase 2, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients with Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT) |
Prof. POON Wai Sang 潘偉生 |
| 2020.258 | A Phase 2, Single Arm, Multi-center, Open-Label Trial to Evaluate the Safety and Efficacy of Treatment with Tumor Treating Fields (TTFields) and Chemotherapy as First-Line Treatment for Subjects with Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Gastric (GC) Adenocarcinoma. |
Prof. YEO Winnie 楊明明 |
| 2015.579 | A Phase 2, Uncontrolled, Three-Stage, Dose-Escalation Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical Activity of OMS721 in Adults with Thrombotic Microangiopathies |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2022.448 | A Phase 2/3 Double-Masked, Randomized, 2-stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema |
Prof. CHEN Guy Lijia 陳理佳 |
| 2002.231 | A Phase 2/3 Open Label Multicenter Study of Doxorubicin Hydrochloride Adsorbed to Magnetic Targeted Carriers Administered by Intrahepatic Delivery Versus Intravenous Doxorubicin for Treatment of Patients with Unresectable Hepatocellular Carcinoma( Revised : CRE-2002.150-T) | Prof. Mok Tony |
| 2021.641 | A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2013.296 | A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX855) Administered for Prophylaxis and Treatment of Bleeding in Previously Treated Patients with Severe Hemophilia A | Dr. Wong Siu Ming Raymond |
| 2025.491 | A Phase 2/3, Multicenter, Open-label Trial to Evaluate the Long-term Safety, Tolerability, and Efficacy of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2025.660 | A PHASE 2/3, MULTICENTER, RANDOMIZED OPEN-LABEL STUDY OF ZANZALINTINIB VS EVEROLIMUS IN PARTICIPANTS WITH PREVIOUSLY TREATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NEUROENDOCRINE TUMORS | Prof. CHAN Stephen Lam |
| 2003.088 | A Phase 2/3, Multicenter, Randomized, Controlled, Open-Label Study of Intravenous T138067-Sodium versus Intravenous Doxorubicin in Subjects with Chemotherapy-Na_ve, Unresectable Hepatocellular Carcinoma | Prof. Mok SK Tony |
| 2008.100 | A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atacicept in Subjects with Lupus Nephritis in Combination with Mycophenolate Mofetil Therapy | Prof. Szeto Cheuk Chun |
| 2020.310 | A Phase 2a, Multicenter, Single-Blind, Placebo-Controlled Study Evaluating Treatment Intensification with ABI-H0731 in Subjects with Chronic Hepatitis B Infection on Nucleos(t)ide Reverse Transcriptase Inhibitors | Prof. WONG Grace Lai Hung |
| 2020.509 | A Phase 2a, Multicenter, Single-Blind, Placebo-Controlled, Multiple Cohort Study Evaluating ABI-H2158-Containing Regimens in Chronic Hepatitis B Infection |
Prof Wong Grace Lai Hung 黃麗虹 |
| 2024.002 | A Phase 2a, Open-Label Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Imdusiran (AB-729) in Combination with Intermittent Dosing of Durvalumab, a PD-L1 Monoclonal Antibody, in Subjects with Chronic HBV Infection | Prof. WONG Grace Lai Hung |
| 2021.402 | A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) | Dr. YIP Wai Man |
| 2021.427 | A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) |
Prof. WONG Grace Lai Hung 黃麗虹教授 |
| 2022.656 | A Phase 2a, Randomized, Blinded, Multicenter Study Investigating a Combination of AB-729 and VTP-300 in Virologically-Suppressed Chronic Hepatitis B Participants | Prof. WONG Grace Lai Hung |
| 2009.429 | A Phase 2A, Randomized, Double-Blind, Active and Placebo-Controlled Study of PF-04171327 in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis | Dr. TAM Lai-Shan |
| 2018.104 | A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and in Combination With a Nucleos(t)ide Analog in Subjects With Chronic Hepatitis B Virus Infection |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2020.602 | A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis |
Prof. WONG Vincent Wai Sun 黃煒燊教授 |
| 2020.557 | A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis | Prof. KONG Alice Pik Shan |
| 2023.249 | A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Precirrhotic Nonalcoholic Steatohepatitis | Prof. WONG Vincent Wai Sun |
| 2019.540 | A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). |
Dr. TAM Lai Shan 譚麗珊 |
| 2024.460 | A Phase 2b, multi-centre, randomized, partially placebo-controlled, double-blind study to investigate the safety and efficacy of sequential therapy with daplusiran/tomligisiran followed by bepirovirsen in participants with chronic hepatitis B virus on background nucleos(t)ide analogue therapy (B-United) | Prof. WONG Grace |
| 2019.415 | A Phase 2b, Multicenter, Double-blind, Active Controlled, Randomized Study to Investigate the Efficacy and Safety of different combination regimens including JNJ-73763989 and/or JNJ-56136379 for the treatment of Chronic Hepatitis B Virus Infection | Prof. WONG Vincent Wai Sun |
| 2023.182 | A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of HTD1801 in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis who Have Type 2 Diabetes or Pre-Diabetes (The CENTRICITY Study) | Prof. WONG Vincent Wai Sun |
| 2023.260 | A phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (S-005151) compared with placebo in adult participants with acute ischemic stroke | Prof. LEUNG Thomas Wai Hong |
| 2023.151 | A phase 2b, open-label study to evaluate the efficacy, safety, tolerability, immunogenicity and treatment regimens of VTP-300 combined with low-dose nivolumab in Chronic Hepatitis B Infection |
Prof. WONG Grace Lai Hung Grace LH Wong |
| 2024.628 | A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Dose Range-Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 Given Once Daily for 12 Weeks in Adults with Uncontrolled Asthma at Risk of Exacerbations (LEVANTE) | Prof. HUI David Shu Cheong |
| 2015.635 | A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults with Respiratory Syncytial Virus (RSV) Infection |
Prof. LEE Nelson Lai Shun 李禮舜 |
| 2009.526 | A Phase 2B, randomized, double-blind, placebo-controlled, dose ranging study evaluating the efficacy and safety of tanezumab for the treatment of moderate to severe pain associated with interstitial cystitis / painful bladder syndrome (IC/PBS) | Dr. Chan Shing Chee |
| 2009.528 | A Phase 2B, Randomized, Double-blind, Placebo-Controlled, Dose Ranging Study Evaluating the Efficacy and Safety of Tanezumab for the Treatment of Moderate to Severe Pain Associated with Interstitial Cystitis / Painful Bladder Syndrome (IC/PBS) | Dr. Ng Chi Fai |
| 2024.429 | A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN) | Prof. SZETO Cheuk Chun |
| 2013.604 | A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA AT RISK OF CARDIOVASCULAR EVENTS | Dr. SO Wing Yee |
| 2011.263 | A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, SAFETY AND EFFICACY STUDY OF ONCE DAILY CONTROLLED RELEASE PREGABALIN IN THE TREATMENT OF PATIENTS WITH POSTHERPETIC NEURALGIA | Prof. GIN Tony |
| 2019.150 | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937) |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2013.658 | A PHASE 3 DOUNLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDMIA AT RISK OF CARDIOVASCULAR EVENTS | Prof. YAN Bryan Ping Yen |
| 2020.156 | A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants with Persistent or Chronic Primary Immune Thrombocytopenia (ITP) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.642 | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012) |
Prof. CHAN Stephen Lam 陳林教授 |
Page 18 of 271.